Biocon

---

title: "Biocon" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["biotechnology-companies-of-india", "pharmaceutical-companies-established-in-1978", "pharmaceutical-companies-of-india", "manufacturing-companies-based-in-bengaluru", "biotechnology-companies-established-in-1978", "indian-companies-established-in-1978", "indian-brands", "1978-establishments-in-karnataka", "companies-listed-on-the-national-stock-exchange-of-india", "companies-listed-on-the-bombay-stock-exchange"] description: "Indian multinational biopharmaceutical company" topic_path: "geography/india" source: "https://en.wikipedia.org/wiki/Biocon" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Indian multinational biopharmaceutical company ::

::data[format=table title="Infobox company"]

Field	Value
name	Biocon Limited
logo	Biocon Logo.svg
image	Bangalore Biocon.jpg
image_caption	Headquarters at Electronic City, Bangalore
type	Public
traded_as

| | founder | Kiran Mazumdar-Shaw | | key_people | {{ubl | | ISIN | | | industry | | | products | | | revenue | (2025) | | operating_income | (2025) | | net_income | (2025) | | assets | (2025) | | equity | (2025) | | num_employees | 16,545 (March 2023) | | subsid | | | foundation | | | location_city | Bengaluru, Karnataka | | location_country | India | | homepage | | | footnotes | Financials . | ::

| name = Biocon Limited | logo = Biocon Logo.svg | image = Bangalore Biocon.jpg | image_caption = Headquarters at Electronic City, Bangalore | type = Public | traded_as =

| founder = Kiran Mazumdar-Shaw | key_people = {{ubl |Kiran Mazumdar-Shaw (executive chairperson) |Peter Bains (Group CEO) |Siddharth Mittal (CEO & Managing Director) |Shreehas P Tambe (CEO & Managing Director, Biocon Biologics Limited) | ISIN = | industry = | products = | services = | revenue = (2025) | operating_income = (2025) | net_income = (2025) | assets = (2025) | equity = (2025) | num_employees = 16,545 (March 2023) | subsid = | intl = | foundation = | slogan = | location_city = Bengaluru, Karnataka | location_country = India | homepage = | footnotes = Financials .

Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).

Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research and development organization.

History

Biocon was founded in 1978 with US$10,000 as the initial capital by a Kiran Mazumdar who was born to Gujarati parents in Bangaluru.

In 1979, Biocon became the first Indian company to manufacture and export enzymes to the US and Europe.

In 1989, Unilever acquired Biocon Biochemicals Ltd. in Ireland and merged it with its subsidiary Quest International. Biocon received US funding for proprietary technologies.

In 1994, Biocon established Syngene International as a custom research company.

During 1998, Unilever agreed to sell its shareholding in Biocon to the Indian promoters. Biocon became an independent entity.

In 2001, Biocon became the first Indian company to be approved by the USFDA for the manufacture of lovastatin; PlaFractor was granted a US 2001 and worldwide patent.

In 2003, Biocon became the first company worldwide to develop human insulin on a pichia expression system.

In 2006, BIOMAb EGFR, the first indigenously developed humanised monoclonal antibody for head-and-neck cancer, was launched, and APJ Abdul Kalam inaugurated India's largest biotech-hub, Biocon Park.

In 2008, Biocon acquired a 70% stake in German pharmaceutical company AxiCorp GmbH.

During 2009, a Syngene-Bristol Myers Squibb research facility was established in Bengaluru.

Later in 2009, Mylan announced a strategic collaboration with Biocon to enter the global generic biologics market.

In 2010, Biocon expanded to Malaysia, with a biopharmaceutical manufacturing and R&D facility established in Iskandar, Johor.

In 2012, Abbott announced a collaboration with Syngene to open the first nutrition R&D center in India.

During 2013, Biocon launched the biologic drug ALZUMAb to treat psoriasis.

During 2014, Biocon launched the first biosimilar drug, CANMAb, to treat breast cancer.

In 2015, Biocon launched a hepatitis-C drug in India under the brand name CIMIVIR-L.

In 2016, Biocon became the first Indian company to launch a biosimilar insulin glargine pen in Japan.

During 2016, Syngene set up an Amgen R&D center in Bangalore.

In 2017, Biocon's Insugen became the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.

In 2017, USFDA approved Mylan-Biocon's biosimilar for the cancer drug Herceptin.

During 2018, Biocon and Mylan received the European Commission's approval to market the biosimilar insulin glargine.

During 2021, Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together. Another aspect of the deal involved Bicocon selling 15% of its biologics subsidiary to the Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.

During 2022, Biocon Biologics bought the biosimilar assets of Viatris for $3.34 billion.

Corporate governance

::figure[src="https://upload.wikimedia.org/wikipedia/commons/0/06/STR_6036.jpg" caption="Kiran Mazumdar-Shaw is an Indian entrepreneur. She founded Biocon in 1978."] ::

Biocon's CMD Kiran Mazumdar-Shaw joined Biocon in 1978. Her efforts in biotechnology have drawn global recognition both for the industry in India and for Biocon. She was called India's "biotech queen" by The Economist and India's "mother of invention" by The New York Times. She was named among Time magazine's 2010 100 most influential people in the world, not only due to her contribution to the biotech industry, but also because she gives back to the community. Shaw has been featured on the Forbes list of "The World's 100 Most Powerful Women" and in the Financial Times "Top 50 Women in Business" list.

Shaw is the recipient of several awards including the Nikkei Asia Prize, 2009 for Regional Growth, Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur, The Economic Times 'Businesswoman of the Year', the 'Veuve Clicquot Initiative For Economic Development For Asia, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, 'Technology Pioneer' recognition by World Economic Forum and the Indian Chamber of Commerce Lifetime Achievement Award. She has received two Indian national awards, the Padma Shri (1989) and Padma Bhushan (2005), for her pioneering efforts in industrial biotechnology.

Christiane Hamacher was appointed as the CEO of Biocon Biologic India Limited, with her term starting in March 2019.

On 3 December 2019, Siddharth Mittal took over from Arun Chandavarkar, who retired as CEO and joint managing director of Biocon.

In 2021, Hamacher resigned from her position, following differences with Kiran Mazumdar-Shaw.

Subsidiaries

Biocon Biologics

::figure[src="https://upload.wikimedia.org/wikipedia/commons/9/93/Biocon_Park_.jpg" caption="Inside Biocon Research Centre in Biocon Park, [[Bommasandra]], [[Bangalore"] ::

Biocon Biologics is Biocon's biosimilar subsidiary. In 2021, Biocon and Viatris received approval to launch Semglee, an insulin glargine-yfgn injection, the first interchangble biosimilar for diabetes in the United States. In 2021, Biocon sold 15% of Biocon Biologics to Serum Institute of India for a valuation of $4.9 billion, for which Biocon will receive access to 100 million doses of vaccines per annum for 15 years. These vaccines will mainly be supplied from Serum Institute's upcoming vaccine facility in Pune, and Biocon will also have the commercialization rights of Serum Institute's vaccine portfolio, which includes the COVID-19 vaccine, for the international markets. In May 2022, Viatris sold its biosimilars division to Biocon Biologics for a price of US$3.335 billion.

Syngene International Ltd

Established in 1993, Syngene International Limited is a contract research and development organization (CDMO). In the CDMO space, Syngene primarily focuses on research innovation and manufacturing services for their clients. The company has four divisions: drug discovery services, dedicated research centres, development devices and manufacturing. Syngene works with eight of the top 10 global pharma companies and, Syngene's clients include Amgen, Zoetis, GlaxoSmithKline and Bristol Myers Squibb. Syngene has been expanding its operations. Since 2020, the company has opened an R&D centre in Hyderabad, is building an API manufacturing facility in Mangalore, which was scheduled to be commissioned in 2022, and has expanded their R&D facility in Bangalore. Syngene also provides biologics CDMO services. In July 2022, Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librela (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs. SynVent is Syngene's drug discovery and development platform for both small and large molecules. In September 2022, Biocon divested 5.4% of its shares in Syngene International.

Clinigene

Clinigene International Limited is a subsidiary of Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.

BBPL

Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.

Biocon-AxiCorp

In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.

NeoBiocon

Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi.

Biofusion Therapeutics Limited

Biofusion Therapeutics Limited was incorporated in March 2021. It is 100% owned by Biocon.

Strategic partnerships

Biocon and Amylin

In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics. Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.

Biocon and IATRICa

In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research. The goal of this collaboration is to develop a therapeutic vaccine where the T cell-mediated immunity is enhanced and maintained against a tumor that otherwise evades immune responses. Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied.

Biocon and Viatris

In 2009, Biocon signed a collaboration agreement with Viatris to develop and commercialize generic biologics. Viatris and Biocon will share development, capital, and other costs to bring products to market. Viatris will have exclusive commercialisation rights in the USA, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries through a profit-sharing arrangement with Biocon.

Biocon and Optimer

Biocon and Optimer Pharmaceuticals, a biopharmaceutical company focused on the treatment of serious infections such as Clostridioides difficile infection (CDI), have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, fidaxomicin.

Biocon and Vaccinex

Biocon is also developing fully human antibodies BVX 10 and BVX-20 with a US antibody technology partner, Vaccinex. The partnership was initiated in 2004. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients with rheumatoid arthritis. Biocon's strategic partnership with Vaccinex allows access to their proprietary human antibody platform technology, thereby providing a strong IP protection to Biocon's antibody pipeline.

Biocon and Abraxis

In 2007, Biocon and Abraxis BioScience, Inc. entered into an agreement that helped Biocon out-license the rights to develop and market a biosimilar version of GCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets.

Biocon and Sandoz

In January 2018, Sandoz (a Novartis division) announced a global partnership with Biocon to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Operations

Biocon's manufacturing facilities are located at two sites in Bangalore.

Biocon's R&D focuses on the entire drug development pathway – from process development to non-clinical and clinical research.

Biocon offers 36 brands of products across the four therapeutic divisions of diabetology, nephrology, oncology, and cardiology.

References

References

1. "Biocon Annual Report 2017". Biocon.
2. "Q4 & Full Year FY25 Earnings Presentation". Biocon.
3. "Audited financial results (standalone and consolidated) of the Company for the quarter and financial year ended March 31, 2025". Biocon.
4. (3 July 2020). "Active Pharmaceutical Ingredient (API)".
5. (2022). "Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US -licensed Humulin® R formulation in healthy subjects: Results from the RHINE -1 ( Recombinant Human INsulin Equivalence-1 ) study". Diabetes, Obesity and Metabolism.
6. Katyal, Surabhi. (2015-06-15). "6 Indian and Indian Origin Women in the list of Forbes 100 Most Powerful Women in the World".
7. nimmi. "Biocon, India's largest biotech company.".
8. Baisya, Rajat K.. (9 September 2010). "Winning Strategies for Business". SAGE Publications India.
9. Pearce. (2009). "Strategic Management 10E". McGraw-Hill Education (India) Pvt Limited.
10. "Biocon Ltd: About Biocon Pharma Company Founder, CEO, Products & Contact Address".
11. "Dr. APJ Abdul Kalam Dedicates India's First Cancer Drug BIOMab EGFR to the Nation and Inaugurates India's Largest Biotech-Hub "Biocon Park" {{!}} Evaluate".
12. "Biocon Acquires 70% Stake in German Pharmaceutical Company, AxiCorp: Biosimilars Will be Main Focus {{!}} Evaluate".
13. Burns, Lawton R.. (13 January 2014). "India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing". Cambridge University Press.
14. "Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market". MediaRoom.
15. (11 September 2011). "Biocon Limited To Build US$161 Million R&D Facility in Bio-XCell, Malaysia". Asian Scientist Magazine {{!}} Science, technology and medical news updates from Asia.
16. Abbott. "Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India".
17. "Biocon unveils biologic drug to treat skin disorder". @businessline.
18. (18 January 2014). "Kiran Mazumdar-Shaw's Biocon develops new breast cancer drug". [[The Times of India]].
19. Pilla, Viswanath. (24 December 2015). "Biocon launches hepatitis-C drug in India". livemint.com/.
20. Pilla, Viswanath. (15 July 2016). "Biocon's partner FUJIFILM launches insulin glargine in Japan". livemint.com/.
21. (6 September 2016). "Indian CRO Syngene sets up Amgen R&D center in Bangalore {{!}} FierceBiotech".
22. "Biocon Wins MYR 300 Million Contract For Insulin From MoH Malaysia".
23. Trivedi, Isha. (2 December 2017). "US FDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin". livemint.com/.
24. (30 March 2018). "Biocon, Mylan get European Commission approval to market biosimilar insulin glargine". Business Medical Dialogues.
25. Das, Sohini. (2021-09-17). "Biocon Biologics, Serum Institute Life Sciences enter strategic alliance". Business Standard India.
26. Rajagopal, Divya. (2022-03-01). "Biocon's unit buys biosimilar assets of Viatris for $3.34 billion".
27. (2 March 2019). "Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India". Medical Dialogues.
28. (3 December 2019). "Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar". Medical Dialogues.
29. (2021-01-22). "Christiane Hamacher quits as CEO of Biocon Biologics".
30. (2021). "Press Release titled "Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes"".
31. Biocon. (16 September 2021). "Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance".
32. Li, Robert. (March 2, 2022). "Viatris sells biosimilars unit for USD 3.335 billion".
33. Babu, Venkatesha. (2021). "We are co-innovating with global pharma companies: Syngene MD & CEO".
34. Ghosh, Debojyoti. (2021). "Syngene's winning formula".
35. Rughani, Kushal. (10 February 2021). "Initiating Coverage: Syngene International Ltd".
36. (21 January 2022). "Syngene International (SYNINT)".
37. Rautela, Isha. (2022-07-14). "Syngene inks 10-year biologics manufacturing pact with Zoetis".
38. "SynVent Integrated Drug Discovery".
39. Jaiswar, Pooja Sitaram. (2022-09-06). "Biocon divests over ₹1,220 crore stake in Syngene International in bulk deal".
40. (2006-10-29). "Atlas Copco sells majority stake in rental business". Pump Industry Analyst.
41. "Building on a Foundation of IP".
42. "Biocon incorporates wholly-owned subsidiary Biofusion Therapeutics".
43. "Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars {{!}} Novartis".
44. "Biocon Annual Report, 2010".
45. Financial Express, Bangalore, 25 September 2009
46. [http://www.moneycontrol.com/news_html_files/news_attachment/2010/Biocon.pdf "Biocon Biopharmaceuticals becomes wholly owned subsidiary"], Moneycontrol.com, 6 April 2010
47. Biotech Bonanza, India Today, 9 August 2004 (http://www.avesthagen.com/press/it.html)
48. [http://www.hindu.com/mp/2010/04/27/bangindx.htm], The Hindu, Metro Plus, 27 April 2010 {{Webarchive. link. (2 May 2010)
49. Kiran Mazumdar-Shaw, CMD, Biocon Ltd, [http://www.outlookmoney.com/article.aspx?88528 'Biotech Is Not for Punters'], Outlook Money, 15 July 2004
50. Economic Times, 18 September 2006
51. [http://www.technologyreview.in/biomedicine/23610/ "Biocon Injects Innovation Gene"] {{Webarchive. link. (17 July 2011 , Technology Review, October 2009)
52. "Biocon - Biosimilars, Fermentation, Oral Insulin, Human Insulin, Immunosuppresants, Monoclonal Antibody, Recombinant Proteins, Biopharmaceutical, Biotechnology Company, EGFR, GCSF, Fermentation, Orlistat, Insulin Glargine, Insulin Lispro, Peptides, Insulin Aspart".
53. Nature Reviews Drug Discovery, July 2010
54. Biospectrum India Friday, 11 July 2008
55. Kiran Mazumdar Shaw, India's fermentation queen, 30 August 2001
56. [https://www.nytimes.com/2003/08/16/world/the-saturday-profile-how-india-s-mother-of-invention-built-an-industry.html "How India's Mother of Invention Built an Industry"], 16 August 2003
57. ''Time'', 29 April 2010
58. The World's 100 Most Powerful Women, Forbes, 19 August 2009
59. ''FT'' top 50 women in world business, ''Financial Times'', 25 September 2009
60. India's biotech future, Kiran Mazumdar-Shaw, ''The Hindu'', 15 August 2007
61. The Hindu, 12 May 2009
62. Data shows declining productivity in drug R&D, Reuters, 27 June 2010
63. The Pharmerging Future, IMS Health, June 2009
64. Biocon, IATRICa to co-develop drugs, ''Business Standard'', Bangalore, 17 January 2008

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::